{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:04:41Z","timestamp":1793156681452,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T00:00:00Z","timestamp":1299801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p>\n                    <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\u2022\u2003The pharmacogenetic polymorphisms of both TPMT and ITPA are associated with individual variability in 6\u2010mercaptopurine (6\u2010MP) intracellular metabolism.<\/jats:p>\n                  <jats:p>\u2022\u2003The balance between red blood cell (RBC) 6\u2010thioguanine nucleotide (6TGN) and 6\u2010methylated metabolite (6\u2010MMPN) concentrations has an important impact on efficacy in children treated for acute lymphoblastic leukemia.<\/jats:p>\n                  <jats:p>\u2022\u2003Hepatotoxicity is a frequent complication of the association 6\u2010MP and methotrexate during maintenance therapy.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\u2022\u2003RBC 6\u2010TGN concentrations are dependant on TPMT genotype and age, while RBC 6\u2010MMPN concentrations depend on TPMT and ITPA polymorphisms.<\/jats:p>\n                  <jats:p>\u2022\u2003Children aged 6 years or less had lower RBC 6\u2010TGN concentrations during maintenance therapy, demonstrating an age effect on 6\u2010MP intracellular metabolism.<\/jats:p>\n                  <jats:p>\n                    \u2022\u2003Hepatotoxicity is a frequent complication of the association of 6\u2010MP and methotrexate. A 6\u2010MMPN threshold of 5000\u2003pmol\/8 \u00d7 10\n                    <jats:sup>8<\/jats:sup>\n                    RBC was associated with an increased risk of hepatotoxicity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>AIMS<\/jats:bold>\n                    6\u2010mercaptopurine (6\u2010MP) is used in the treatment of childhood acute lymphoblastic leukaemia (ALL). Its red blood cell (RBC) metabolite concentrations (6\u2010thioguanine [6\u2010TGN] and 6\u2010methylmercaptopurine nucleotides [6\u2010MMPN]) are related to drug response. We investigated the impact of non\u2010genetic covariates and pharmacogenetic polymorphisms affecting thiopurine methyltransferase (\n                    <jats:italic>TPMT<\/jats:italic>\n                    ) and inosine triphosphate pyrophosphatase (\n                    <jats:italic>ITPA<\/jats:italic>\n                    ) on 6\u2010MP metabolism and response.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>METHODS<\/jats:bold>\n                    Sixty\u2010six children with ALL treated according to EORTC 58951 protocol were included in this study. Six patients had a heterozygous genotype for the most common\n                    <jats:italic>TPMT<\/jats:italic>\n                    polymorphisms, nine for\n                    <jats:italic>ITPA 94 C<\/jats:italic>\n                    &gt;\n                    <jats:italic>A<\/jats:italic>\n                    and 17 for\n                    <jats:italic>ITPA IVS2<\/jats:italic>\n                    +\n                    <jats:italic>21 A<\/jats:italic>\n                    &gt;\n                    <jats:italic>C<\/jats:italic>\n                    . 6\u2010MP metabolites concentrations were analyzed by mixed model analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS<\/jats:bold>\n                    During maintenance, steady\u2010state RBC 6\u2010TGN concentrations were lower in patients aged 6 years or younger (493\u2003pmol\/8 \u00d7 10\n                    <jats:sup>8<\/jats:sup>\n                    RBC) than in older children (600\u2003pmol\/8 \u00d7 10\n                    <jats:sup>8<\/jats:sup>\n                    RBC). 6\u2010MMPN concentrations were low in patients with\n                    <jats:italic>TPMT<\/jats:italic>\n                    variant\/wild\u2010type\n                    <jats:italic>ITPA<\/jats:italic>\n                    (1862\u2003pmol\/8 \u00d7 10\n                    <jats:sup>8<\/jats:sup>\n                    RBC), intermediate in wild\u2010type patients and high (16468\u2003pmol\/8 \u00d7 10\n                    <jats:sup>8<\/jats:sup>\n                    RBC) in patients wild\u2010type\n                    <jats:italic>TPMT<\/jats:italic>\n                    \/variant\n                    <jats:italic>ITPA<\/jats:italic>\n                    . A 6\u2010MMPN threshold of 5000\u2003pmol\/8 \u00d7 10\n                    <jats:sup>8<\/jats:sup>\n                    RBC was associated with an increased risk of hepatotoxicity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION<\/jats:bold>\n                    In this study, age and both\n                    <jats:italic>TPMT<\/jats:italic>\n                    and\n                    <jats:italic>ITPA<\/jats:italic>\n                    genotypes influenced 6\u2010MP metabolism. High 6\u2010MMPN was associated with hepatotoxicity. These pharmacological tools should be used to monitor ALL treatment in children.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03867.x","type":"journal-article","created":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T06:05:53Z","timestamp":1290751553000},"page":"575-584","source":"Crossref","is-referenced-by-count":120,"title":["Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy"],"prefix":"10.1111","volume":"71","author":[{"given":"Tiphaine","family":"Adam de Beaumais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Fakhoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Medard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Azougagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daolun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Yakouben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Jacqz\u2010Aigrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,11]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(02)00106-8"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054528"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.2.201"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.345"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402373"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112088"},{"key":"e_1_2_7_9_2","first-page":"80","article-title":"Cellular pharmacology of 6\u2010mercaptopurine in acute lymphoblastic leukemia","volume":"15","author":"Bostrom B","year":"1983","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2649979"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1800"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70354-4"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401723"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0478-6"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199703000-00002"},{"key":"e_1_2_7_16_2","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events version 2.0 (CTCAE). Published April 30 1999. Available at:http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcv20_4\u201030\u2010992.pdf"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.050831"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20387"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903426151"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199510000-00003"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1184-5"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200403000-00006"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03281.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2006.10.006"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0026-895X(25)08754-1","article-title":"Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S\u2010methyltransferase","volume":"47","author":"Krynetski EY","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-002-0798-z"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.12.001"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1560"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03248.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03867.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03867.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T01:49:39Z","timestamp":1740707379000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03867.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,11]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03867.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03867.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,11]]}}}